Wegovy Pre-filled Pen 1.7 (Semaglutide)

Adult administration

Start at 0.25 mg once weekly and gradually increase over 16 weeks reaching a maintenance dose of 2.4 mg once weekly. The dosage escalation schedule is 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, and 1.7 mg for weeks 13 to 16, with a maintenance dose of 2.4 mg. Dosing above 2.4 mg once weekly is not recommended. Administer subcutaneously, regardless of meals.

Child administration

Adolescents aged 12 and older should follow the same dosage escalation schedule as adults. The maintenance dose is administered once weekly at 2.4 mg or until the maximum tolerable dose is reached.

This medication should not be used in patients with allergies to the active ingredient or excipients. Patients in a dehydrated state should exercise caution when using this medication, as gastrointestinal side effects may increase the risk of fluid depletion, necessitating adequate hydration and preventative measures. Patients with a history of acute pancreatitis or suspected pancreatitis symptoms should discontinue use of this medication, and it should not be reused once pancreatitis is confirmed. This medication should not be used as a substitute for insulin in patients with type 2 diabetes, and concomitant use with other GLP-1 receptor agonists should be avoided. When used with insulin or sulfonylureas, there may be an increased risk of hypoglycemia, thus patients should be educated on hypoglycemia symptoms and the dosage of these medications adjusted as needed. Patients with diabetic retinopathy may experience worsening of retinopathy while using this medication, necessitating regular ophthalmological examinations and close monitoring. This medication is not recommended for patients taking other medications for weight management, patients with type 1 diabetes, those with severe renal or hepatic impairment, and patients with severe heart failure. Gastrointestinal side effects can occur frequently with this medication, and symptoms such as nausea, vomiting, diarrhea, and constipation may arise, so patients should consult healthcare professionals if symptoms are severe. This medication can delay gastric emptying, affecting the absorption of other oral medications, requiring caution if other medications are being taken concurrently. Women who are pregnant or planning to become pregnant should not use this medication, and breastfeeding women should also avoid its use. No special dosage adjustment is required for elderly patients, but caution should be exercised in those over 75 years of age due to increased risk of fractures. When using this medication, it is important to learn proper injection techniques, change the needle each time, and not share it with others. Store this medication out of reach of children, in a refrigerator while avoiding freezing.

• Nausea
• diarrhea
• constipation
• vomiting
• headache
• dizziness
• taste disorder
• abnormal sensation
• hypoglycemia
• diabetic retinopathy

This medication should be stored in a sealed container to prevent exposure to air and kept refrigerated at a temperature between 2 to 8 degrees Celsius, while being protected from freezing. It is also advisable to store it in a dark place to avoid direct sunlight.

Appearance

A pre-filled pen equipped with a dosing adjustment mechanism, containing a colorless or nearly colorless transparent liquid in a colorless transparent cartridge.

Package unit

1 pre-filled pen/box [pre-filled pen (3mL)]